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Abstract
Background: The VRK1 chromatin kinase regulates the organization of locally altered chromatin induced by DNA
damage. The combination of ionizing radiation with inhibitors of DNA damage responses increases the
accumulation of DNA damage in cancer cells, which facilitates their antitumor effect, a process regulated by VRK1.
Methods: Tumor cell lines with different genetic backgrounds were treated with olaparib to determine their effect
on the activation of DNA repair pathways induced by ionizing radiation. The effect of combining olaparib with
depletion of the chromatin kinase VRK1 was studied in the context of double-strand breaks repair pathway after
treatment with ionizing radiation. The initiation and progression of DDR were studied by specific histone
acetylation, as a marker of local chromatin relaxation, and formation of γH2AX and 53BP1 foci.
Results: In this work, we have studied the effect that VRK1 by itself or in collaboration with olaparib, an inhibitor of
PARP, has on the DNA oxidative damage induced by irradiation in order to identify its potential as a new drug
target. The combination of olaparib and ionizing radiation increases DNA damage permitting a significant reduction
of their respective doses to achieve a similar amount of DNA damage detected by γH2AX and 53BP1 foci. Different
treatment combinations of olaparib and ionizing radiation permitted to reach the maximum level of DNA damage
at lower doses of both treatments. Furthermore, we have studied the effect that depletion of the VRK1 chromatin
kinase, a regulator of DDR, has on this response. VRK1 knockdown impaired all steps in the DDR induced by these
treatments, which were detected by a reduction of sequential markers such as H4K16 ac, γH2AX, NBS1 and 53BP1.
Moreover, this effect of VRK1 is independent of TP53 or ATM, two genes frequently mutated in cancer.
Conclusion: The protective DNA damage response induced by ionizing radiation is impaired by the combination
of olaparib with depletion of VRK1, and can be used to reduce doses of radiation and their associated toxicity.
Proteins implicated in DNA damage responses are suitable targets for development of new therapeutic strategies
and their combination can be an alternative form of synthetic lethality.
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Background
Therapies targeting to DNA damage response (DDR)
pathways are becoming a model for identification of
suitable novel combination therapies, which include
inhibition of DNA repair mechanisms and chromatin
regulation [1, 2]. One mainstay of cancer treatment is
based on the generation of catastrophic DNA damage
in tumor cells, particularly those that directly damage
DNA, which include ionizing radiation (IR), among
others. IR generates reactive oxygen species that at-
tacks DNA mostly causing single-strand, and if not
repaired, double-strand breaks. Therefore, interference
with DNA repair (DDR) mechanisms can facilitate
and increase the amount of DNA damage in cells. In
this context, new drugs have been developed for tar-
geting DNA repair processes and for use in tumors
with deficiency in DDR pathways, generally linked to
ATM and BRCA mutations.
DNA damage causes a local distortion of chromatin,
which triggers several sequential reactions in order to
start the appropriate DNA damage response (DDR) [3,
4]. These sequential steps range from a local chromatin
relaxation and remodeling, and protection of DNA at
damaged sites, to the recognition of the type of damage
and the activation of its specific DDR pathway. Among
these early events is histone acetylation, which is associ-
ated with a local chromatin relaxation that facilitates ac-
cessibility to the proteins in the DDR sequential steps,
which include phosphorylation of H2AX and recruit-
ment of DNA repair proteins, such as NBS1, NBS1 and
53BP1, implicated in Non-homologous end-joining
(NHEJ), a key DDR pathway in resting cells.
Olaparib is an inhibitor of poly-ADP ribose polymer-
ase (PARP), a component of the base-excision repair
(BER), that is involved in the repair of DNA damage
caused by oxidative stress [5, 6]. Because of that, PARP
has become an important therapeutic target [7]. Ola-
parib inhibits end-joining mediated by PARP [8] and
sensitizes cells to DNA damage induced by ionizing radi-
ation [9–12]. The interference of this repair pathway
with olaparib facilitates that single-strand breaks become
double-strand breaks, promoting the accumulation of
DNA damage and the subsequent cell death [13]. There-
fore, PARP inhibitors, such as olaparib, confer cytotox-
icity in response to high levels of reactive oxygen species
[14] and are used in the treatment of tumors lacking
ATM [15, 16] or BRCA1 [17, 18], which are deficient in
DDR and more sensitive to genotoxic treatment.
Targeting DDR is a form of cancer treatment [1]. The
sequential steps in DDR require a coordination that is
mediated by the chromatin kinase VRK1 [19]. The VRK1
kinase appeared late in evolution in higher eukaryotes
and is regulated independently of the type of DNA dam-
age [20]. The chromatin and nucleosomal-kinase VRK1
[19, 21] is a Ser-Thr kinase associated to processes that
require a dynamic chromatin remodeling, including cell
proliferation [22] and DNA damage responses [19, 20,
23, 24]. VRK1 participates in these events by its direct
involvement in specific repair processes at different se-
quential stages. Initially, VRK1 depletion impairs chro-
matin remodeling by regulating histone acetylation [24,
25], required for relaxation of chromatin at sites of DNA
breaks [24]. Later in the response, VRK1 depletion also
impairs specific steps in pathway involved in DNA repair
and interferes with the formation of γH2AX [24], NBS1
[23] or 54BP1 [20] foci. Thus, the combination of VRK1
with ionizing radiation or doxorubicin results in an in-
creased sensitivity to these commonly used treatments
[26]. In this context, high levels of VRK1 confers resist-
ance to doxorubicin treatment [26]. Furthermore, high
VRK1 levels are also associated to very poor prognosis
in many types of carcinomas with different origin and
genetic background [27–30].
It is becoming very evident that combinations of treat-
ments might result in improvement of cancer treatment
based on synthetic lethality, and, at the same time, re-
quire the use of a lower drug dosage with respect to
their individual use, which can also have the benefit of a
reduced toxicity. In this work we have studied the effect
that VRK1 depletion has on the cellular response to ola-
parib, a drug which is currently used to sensitize tumor
cell to ionizing radiation, and facilitates tumor elimin-
ation in cells with altered DNA repair pathways, such as
those with BRCA1 [17, 18] or ATM [15, 16] mutations.
Based on this, we postulated that kinases that regulate
sequential steps in DDR mechanisms are potential drug
targets that can sensitize tumor cells to chemotherapy
and IR because of an impaired DDR, which will result in
a loss of tumor cell viability, particularly if these tumors
have mutations in ATM, BRCA1 or TP53 genes. There-
fore, the identification of new drug combinations target-
ing different DDR pathways will be a suitable form of
treatment and lead to a reduction in doses of the current
therapies, which are frequently very toxic for cancer
patients.
Materials and methods
Reagents and inhibitors
Olaparib was from LC Laboratories (Woburn, MA,
USA), and KU55933, from Tocris Bioscience (Bristol,
UK). All other reagents were from Sigma-Aldrich-Merck
(Darmstadt, Germany).
Cell lines and culture
MDA-MB-231 (triple negative), A549 (TP53+/+) and
HT144 (ATM−/−) cell lines were obtained from the
ATCC and grown as recommended by the supplier in
DMEM supplemented with antibiotics, 10% FBS and 5
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mM glutamine. H1299 (TP53−/−) cell line was grown in
RPMI medium supplemented with antibiotics, 10% FBS
and 5mM glutamine. All cell lines are mycoplasma free.
RNA interference
The depletion of VRK1 by siRNA has been previously re-
ported for A549 [20, 23], H1299 [20, 23], MDA-MB-231
[26] and HT144 [23, 24] cell lines. Specific VRK1 knock-
down was performed using siVRK1–02 from DHARMA-
CON RNA Technologies. The target sequences of this
siVRK1–02 is the following one (5′ to 3′): CAAGGAAC-
CUGGUGUUGAA. The “ON-TARGETplus siCONTROL
Non-targeting siRNA” from DHARMACON was used as
negative control (siCtrl) [31]. Briefly, cells were transfected
with the indicated siRNA at a concentration of 20 nM
using either Lipofectamine 2000 (Invitrogen) or Lipotrans-
fectin (Nivorlab), following manufacturer’s instructions
[25, 31, 32].
DNA damage
DNA damage was induced by ionizing radiation with
0.5, 1 or 3 Gy using a Gammacell 1000 Elite irradiator
(Theratronics, Ottawa, Canada) with a 137Cs source, and
exposure to different concentrations of Olaparib (PARP
inhibitor, LC Laboratories; Woburn, MA, USA), or their
combinations, as indicated in the corresponding experi-
ments. The doses of olaparib were added to the culture
for twenty-four hours before irradiation.
Cell lysates and acid extraction of histones
Protein extracts were performed using two different lysis
buffers, “Suave” and RIPA, depending on the cell line. The
“Suave” lysis buffer was composed by 50mM Tris–HCl
(pH 8.0), 1 mM EDTA, 150mM NaCl, and 1% Triton
X-100, while the RIPA one contained 150mM NaCl, 1.5
mM MgCl2, 10mM NaF, 4mM EDTA, 50mM Hepes, 1%
Triton X-100, 0.1% SDS, and 10% glycerol. In both cases,
these buffers also contained phosphatases inhibitors (1
mM NaF and 1mM sodium orthovanadate) and proteases
inhibitors (1mM PMSF, 10 μg/mL aprotinin, and 10 μg/
mL leupeptin), which were added before starting the lysis
itself. Acidic extracts of histones were performed as previ-
ously reported [33]. Protein extracts were quantified using
the Bradford protein assay (Bio-Rad; Hercules, CA) in
order to load the same amount of these extracts in each
well of the polyacrylamide gel, and boiled at 100 °C in
Laemmli buffer for 5min [32, 34].
Antibodies
All the antibodies are listed in Table 1. These antibodies,
used in immunoblots and/or immunofluorescence as-
says, were diluted in TBS-0.1% Tween20 or PBS-1%
BSA, respectively.
SDS-page electrophoresis and western blot analysis
Proteins were fractionated by SDS-Page vertical electro-
phoresis and transferred to Immobilon-FL membranes
(Millipore). The membranes were blocked with TBS-T
buffer (25 mM Tris-HCl (pH 8), 50 mM NaCl, 2.5 mM
KCl, 0.1% Tween-20) and 5% nonfat dry milk, for 1 h at
room temperature. Blocked membranes were incubated
with the primary antibody (listed in Table 1) for an add-
itional 1 h at room temperature or overnight at 4 °C,
followed by extensive washing in TBS-T buffer (3 × 10
min). Next, membranes were incubated with the corre-
sponding secondary antibodies (Table 1) for 1 h in dark-
ness, followed by three washes with TBS-T buffer.
Finally, membrane signals were detected using the
Table 1 List of antibodies and conditions used in this work
Antibody Dilution (WB/IF) Clone and/or reference Supplier
53BP1 Rabbit polyclonal -; 1/200 H300, sc-22,760 Santa Cruz Biotechnology
53BP1 Rabbit polyclonal -; 1/200 NB100–304 Novus Biologicals
Histone H4-K16 ac Rabbit monoclonal 1/500; 1/400 ab109463 Abcam
Nbs1 Mouse monoclonal -; 1/200 611,871 BD Biosciences
VRK1 Mouse monoclonal 1/1000; 1/200 1B5 Own production [74]
VRK1 Rabbit polyclonal 1/1000;- VC Own production [74]
VRK1 (N-term) Rabbit polyclonal -; 1/200 HPA000660 Sigma-Aldrich
β-actin Mouse monoclonal 1/2000; − AC15/A5441 Sigma-Aldrich
γH2AX Mouse monoclonal -; 1/200 Clone JBW301; 05–636 Millipore
Anti-mouse IgG (WB) Goat Anti-Mouse IgG, DyLight 680 (red) 1/10000; − 35,518 Thermo Scientific
Anti-rabbit IgG (WB) Goat Anti-Rabbit IgG, DyLight 800 (green) 1/10000; − 35,571 Thermo Scientific
Goat anti-Mouse IgG (IF) Goat anti-Mouse IgG linked to Cy3 (red) -; 1/1000 115–165-146 Jackson ImmunoResearch;
West Grove, PA, USA
Goat anti-rabbit IgG (IF) Goat anti-rabbit IgG linked to Cy2 (green) -; 1/1000 111–225-144 Jackson ImmunoResearch;
West Grove, PA, USA
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LI-COR Odyssey Infrared Imaging System (LI-COR Bio-
sciences; Lincoln, NE, USA).
Immunofluorescence and confocal microscopy
Cells were plated on 60mm dishes with several coverslips,
two for each antibody to be used. Cells on coverslips were
fixed with 3% paraformaldehyde for 30min, and treated
with a solution of glycine 200mM for 15min at room
temperature. Next, these cells were permeabilized with
0.2% Triton X-100 solution in PBS for 30min and blocked
with 1% BSA in PBS for 30min at room temperature or
overnight at 4 °C. For the simultaneous detection of two
proteins, each coverslip was sequentially incubated with the
two primary antibodies, followed by three washes for 10
min in PBS after each antibody. The incubation with the
corresponding secondary antibodies, labeled with Cy2 or
Cy3 (Table 1 section), was performed in darkness for 1 h at
room temperature. After three washes for 10min in PBS,
nuclei were stained with DAPI (4′, 6′-diamidino-2-pheny-
lindole) (Sigma) 1:1000 in PBS for 15min at room
temperature. Finally, cells were washed three times for 10
min in PBS and slides were mounted with Mowiol (Calbio-
chem-Merck, Darmstadt, Germany). Fluorescent images
were acquired with a LEICA SP5 DMI-6000B confocal
microscope (Leica), using the following lasers: Argon (488
nm), DPSS (561 nm) and UV Diode (405 nm). These im-
ages were captured with a 63.0x lens zoomed in 1.5–3×
with a 1024 × 1024 frame and 600Hz scanning speed.
Scanner settings were maintained constant throughout all
samples examined: pinhole (95.6 μm), lasers intensity and
photomultipliers gain and offset. Afterwards, images were
analyzed with ImageJ software (https://imagej.nih.gov/ij/).
Statistical analysis
All these statistical analysis were performed using IBM
SPSS 25 statistics package. Quantitative experiments
were repeated, at least, three times and statistical signifi-
cance was analyzed using Bonferroni adjusted t-tests
(post hoc parametric test) or Dunn’s multiple compari-
son tests (post hoc non parametric test), depending on
whether all samples were adjusted to a normal distribu-
tion or not, respectively. In both cases, the level of sig-
nificance was 0.05 (*, p < 0.05; **, p < 0.01; and ***, p <
0.001). All results are represented as box plots, in which
the box ranges from the end of first quartile to the third
quartile, the line cutting the box represents the median,
and the whiskers extend to the minimum or maximum
observations [35].
Results
Olaparib sensitizes cells to DNA damage induced by
ionizing radiation and is independent of p53
Initially, we studied the effect of several doses of IR, ola-
parib or their combinations using two markers of DNA
damage response (DDR). Phosphorylated histone H2AX
in Ser139 (γH2AX) was used as an early indicator of
DNA damage [36], and 53BP1 as marker of DNA
double-strand break repair by the NHEJ pathway [37],
which are key regulators at different stages of the repair
process [38]. These foci are indirect markers of the ex-
tent of DNA damage and represent stalled repair in
DNA damage areas. The effect of different doses of ola-
parib and IR was determined in lung cancer A549 (TP53
+/+) cells (Fig. 1a), as well as their combination (Fig. 1b).
These results showed that a combination of lower doses
of olaparib and IR on the formation of γH2AX and 53BP1
foci (Fig. 1b) was required to reach a similar effect to those
caused by higher doses of either IR or olaparib individually
used. The quantifications of foci are shown for γH2AX
(Fig. 1c) and 53BP1 (Fig. 1d). These γH2AX and 53BP1
foci indicate the aggregation of these proteins induced by
DNA damage, without an effect on their protein levels in
the short observation times. The combination of lower
doses of olaparib (5 μM) and IR (1Gy) permitted to reach
the same number of γH2AX and 53BP1 foci that were
achieved with the highest dose of radiation (3Gy). This
represented a very significant reduction in the dose of ra-
diation used, from 3 to 1 Gy, to reach a similar amount of
DNA damage.
The p53 tumor suppressor is a mediator of multiple
responses to different types of cellular stress, including
DNA damage, which consequently triggers cell cycle ar-
rest or apoptosis by a complex signaling network [39].
To rule out whether the effect of olaparib on
sensitization to IR is mediated by a p53-dependent
mechanism, a similar experiment was performed in
H1299 (TP53−/−) lung cancer cells (Additional file 2:
Figure S2). The formation of γH2AX and 53BP1 foci in
response to olaparib or IR, and their combination, led to
the same conclusion and they are independent of p53.
The combination of olaparib and IR permitted a reduc-
tion in dose of olaparib, from 10 to 5 μM, and IR, from
3 to 1 Gy, to reach a similar effect on the number of
DNA damaged sites detected by 53BP1 foci. A similar
result was obtained using the breast triple-negative can-
cer cell line MDA-MB-231 (Additional file 3: Figure S3).
Therefore, it can be concluded that the combination of
lower doses of olaparib and IR generates a maximum
level of DNA damage, as detected by the formation of
repair foci, which could only be reached by using higher
doses of olaparib or IR in the absence of their
combination.
VRK1 depletion impairs the acetylation of K16 in histone
H4 induced by olaparib and IR
The first event that occurs following DNA damage is an
aberrant local disruption of chromatin that needs to be
reorganized in order to start and permit the appropriate
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DDR depending on the type of DNA damage. This initial
chromatin relaxation is associated with histone acetyl-
ation [40], which can be monitored by following the
acetylation of histone H4 in K16 [41–43]. This specific
histone acetylation facilitates the access to DNA repair
proteins at damaged sites, and its loss is associated with
a defective DNA repair [44]. Therefore, we studied the
effect on H4K16 acetylation in response to treatment
with olaparib, ionizing radiation or their combination as
well as VRK1 depletion, in different cell types. A
maximal effect was achieved by the combination of olaparib
with IR on H4K16 acetylation fluorescence in H1299 (TP53
−/−) (Fig. 2) and A549 (Additional file 5: Figure S5) lung
cancer cell lines deprived (0.5%) of serum. The combination
of olaparib (5 μM) with 1Gy achieved the same effect on
nuclear H4K16 ac fluorescence as 3Gy only, and depletion
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Fig. 1 Effect of combinations of olaparib and ionizing radiation on the formation of γH2AX and 53BP1 foci in response to DNA damage
in A549 cells. a. Effect of different doses of either olaparib or ionizing radiation on the formation of γH2AX and 53BP1 foci in response
to DNA damage. b. Effect of combinations of olaparib and ionizing radiation on the formation of γH2AX and 53BP1 foci. c. Quantification
of the effect of olaparib and IR by themselves or in combination on the number of γH2AX foci. d. Quantification of the effect of olaparib
and IR, by themselves or in combination, on the number of 53BP1 foci. ns: not significant, *** p < 0.001. The images show the detail of
the subnuclear protein detected. The quantifications were performed using fifty cells from different fields of the experiments (usually
between seven and ten were required). The field images and the image selected for presentation in the main figure are indicated in
Additional file 1: Figure S1
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of VRK1 impaired the level of H4K16ac associated
with chromatin relaxation induced by DNA damage.
This observation suggested that VRK1 depletion com-
prised the correct progression of later stages in the
DDR process. In addition, depletion of VRK1 caused
a cell cycle arrest and prevents cell proliferation [45–
47] and chromatin condensation in mitosis [48, 49].
Consequently, cells will not be able to divide or repair
its damaged DNA.
VRK1 depletion interferes with the DNA damage response
mediated by NBS1
The phosphorylation and activation of NBS1 is an early
step in the DDR response [50, 51], and VRK1 regulates this
phosphorylation [23]. Therefore, we studied the effect of
VRK1 depletion on the NBS1 response to treatment with
olaparib, ionizing radiation or their combination in several
cell lines with different genetic alterations. The combin-
ation of olaparib (5 μM) with 1Gy achieved the same effect
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Fig. 2 Effect of VRK1 depletion on the nuclear fluorescence associated to the acetylation of histone H4 in lysine 16 (H4K16ac ) induced by
olaparib, IR or their combination in H1299 (TP53−/−) cells deprived (0.5%) of serum. a left. Effect of si-Control (siCtrl/siC) on H1299 cells treated
with different doses of olaparib, IR or their combination on nuclear H4K16 ac fluorescence. a right. Effect of si-VRK1 (siVRK1/siV) on H1299 cells
treated with different doses of olaparib, IR or their combination on the acetylation of histone H4 in lysine 16. b. Quantification of the effect of
VRK1 depletion on the increase of nuclear H4K16ac fluorescence induced by DNA damage. c. The immunoblot shows the effect of VRK1
depletion on its protein level. siC: siControl, siV: siVRK1–02. ns: not significant, ** p < 0.01, *** p < 0.001. The images show the detail of the
subnuclear protein detected. The quantifications were performed using fifty cells from different fields of the experiments (usually between seven
and ten were required). The images selected for presentation in the main figure are indicated in Additional file 4: Figure S4. Similar results were
obtained in A549 cells (TP53+/+) (Additional file 5: Figure S5) in serum (0.5%) deprived cells
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on NBS1 nuclear fluorescence as 3Gy only (Fig. 3, control),
as with H4K16ac acetylation. The depletion of VRK1 im-
paired the DNA damage response mediated by NBS1 in
H1299 (TP53−/−) (Fig. 3, Additional file 6: Figure S6),
A549 (Additional file 7: Figure S7), and HT144 (ATM−/−)
cells (Additional file 8: Figure S8) deprived (0.5%) of serum.
These data indicated that the combination of olaparib with
IR permits a reduction in dose of IR and olaparib, and is in-
dependent of ATM or p53.
VRK1 depletion impairs the DNA damage response
triggered by olaparib and IR
DNA damage triggers a local reorganization of chroma-
tin, and olaparib or IR, which interferes with the repair
of oxidative DNA damage and causes oxidative stress,
respectively, can induce this damage. DNA damage trig-
gers a local chromatin reorganization regulated by ki-
nases among which is VRK1 [19]. This chromatin kinase
is necessary for chromatin relaxation and the correct
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Fig. 3 Effect of VRK1 depletion on nuclear NBS1 fluorescence induced by olaparib, IR or their combination in H1299 (TP533−/−) cells arrested by
the absence of serum. A left. Effect of si-Control on H1299 cells treated with different doses of olaparib, IR or their combination on the NBS1
fluorescence. a right. Effect of si-VRK1 on H1299 (TP53−/−) cells treated with different doses of olaparib, IR or their combination on the
accumulation of NBS1 foci in nuclei. b. Quantification of the effect of VRK1 depletion on the increase of nuclear NBS1 fluorescence by
aggregation of this protein induced by DNA damage. Similar results were obtained in A549 (TP53wt) (Additional file 7: Figure S7), and HT144
(ATM−/−) cells (Additional file 8: Figure S8) in the absence of serum (0.5%). c. The immunoblot shows the effect of VRK1 depletion on its protein
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sequential phosphorylation and activation of histone
H2AX [24], NBS1 [23] and 53BP1 [20, 26] in resting
cells, in which double-strand breaks are repaired by the
Non-homologous end-joining pathway [20, 23, 24].
Therefore, we hypothesized that depletion of endogen-
ous VRK1 can interfere with the response to olaparib
and prevented the sequential DNA repair steps. In A549
cells, VRK1 depletion by siRNA resulted in a defective
DDR that was detected as a loss of γH2AX (Fig. 4a), and
53BP1 (Fig. 4b) foci formed in response to DNA dam-
age. These effects are due to the inability of
VRK1-depleted cells to assemble DNA repair complexes
in A549 cells treated with olaparib, IR and their combin-
ation. Furthermore, VRK1 reached its maximum effect
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on impairment of repair foci at lower doses of olaparib
and IR.
The combined DNA damage response to olaparib and IR
is impaired by VRK1 depletion and is independent of
ATM and p53
VRK1 is an activator of p53 in response to DNA damage
[52–54]. This kinase phosphorylates p53 in Thr18,
which prevents its interaction with mdm2 and leads to
its stabilization and accumulation [52, 55]. This activa-
tion of p53 mediated by VRK1 is reverted after DNA is
repaired by an autoregulatory loop implicating autoph-
agy [53]. Moreover, this autoregulation is defective in
lung carcinomas with p53 mutations [53, 56]. Therefore,
we tested whether depletion of VRK1 in HT144 (ATM
−/−) and H1299 (TP53−/−) tumor cell lines could inter-
fere with the response to olaparib. In ATM-defective
cells, VRK1 knockdown resulted in a defective repair re-
action and the loss of γH2AX and 53BP1 foci in re-
sponse to olaparib and IR treatments (Fig. 5). Similar
results were obtained in H1299 cells (Additional file 9:
Figure S9).
ATM inhibition also impairs DDR after treatment with
olaparib
VRK1 is upstream on ATM in DDR [20, 23, 24]. There-
fore, we hypothesized that inhibition of ATM should
cause a similar effect to VRK1 depletion, and impair the
formation of γH2AX and 53BP1 foci induced by olaparib
treatment. A549 cells were treated with the ATM inhibi-
tor KU55933 as well as olaparib and the effect of their
combination was determined. The addition of ATM in-
hibitor KU55933 to A549 cells (Fig. 6) also resulted in a
reduction in the formation of foci induced by olaparib,
which were also sensitive to VRK1 depletion. Thus, a
combination of olaparib with a future inhibitor of VRK1
might be a suitable combination for tumors that are
wild-type ATM.
The initial H4K16 acetylation induced by olaparib is
independent of ATM
The initial response induced by olaparib, because of not
repairing oxidized nucleotides, is a local chromatin relax-
ation that can be detected as an acetylation of histones, an
effect that should be independent of ATM. To test this
possibility, H4K16ac levels induced by olaparib were stud-
ied in cells that are ATM null, or in the presence of ATM
inhibitor in ATM wild-type cells. Olaparib treatment in-
duced an increase in the level of H4K16 ac in HT144
(ATM−/−) cells, which was sensitive to VRK1 depletion
(Fig. 7a; field image in Additional file 10A: Figure S10A).
To further confirm this effect, H4K16ac nuclear fluores-
cence was also determined in A549 (ATM+/+) cells that
were preincubated with the ATM inhibitor KU55933 and
treated with olaparib. In these conditions, H4K16ac was
sensitive to VRK1 depletion as expected (Fig. 7B, left), and
insensitive to the ATM inhibitor KU55933 (Fig. 7b, center;
field image in Additional file 10B: Figure S10B). These ob-
servations indicated that the initial effect of olaparib on
the level of H4K16 ac did not require ATM, and was
dependent on VRK1.
Discussion
Mutations in genes controlling genome stability are
commonly associated with different types of hereditary
cancer. These hereditary mutations increase the risk of
cancer development and facilitate tumor progression.
Somatic mutations in these genes can also occur during
tumor progression if the mutation load does not inter-
fere with cell viability. Therefore, tumors with defects in
DNA repair pathways can become more sensitive to dif-
ferent forms of treatment, as well as more immunogenic
[57, 58]. Moreover, the accumulation of excessive DNA
damage in cells can reduce their viability and lead to
their death. Because of that, induction of DNA damage
by radiation or chemotherapeutic drugs that directly
cause DNA damage is a common mechanism of action
of cancer treatments. However, these therapeutic ap-
proaches frequently have a high toxicity and side effects
leading to incomplete treatments. Therefore, improve-
ment in cancer therapies requires the development of
new strategies or combination therapies, which can re-
duce their toxicity by a decrease in doses employed.
Recently, the development of inhibitors that impair
DNA repair processes and maximize the effects of com-
mon treatments is a new field. Olaparib has been shown
to sensitize cells to these treatments in cells that have
deficiencies in some DNA repair mechanisms and, for
this reason, it has been used in breast and ovarian can-
cer with BRCA1 mutations [17, 18], or in mantle cell
lymphomas with alterations of the ATM pathway [15].
Thus, novel regulators of DNA repair mechanism are
useful for development of new inhibitors to manage can-
cer with a reduced toxicity. In this context, the identifi-
cation of VRK1 as a protein that can impair DDR may
have therapeutic potential (Fig. 8). In fact, VRK1, be-
cause of the structural characteristics of its kinase do-
main, is the kinase with the smaller risk of cross
inhibition with other Ser-Thr kinase inhibitors [59, 60].
The combined use of olaparib with VRK1 inhibitors can
result in cancer treatments with less severe, or fewer,
side effects and toxicity, and thus better tolerated. VRK1
depletion can function in cells lacking ATM or p53 [20,
23, 24, 26], which widens the number of tumor types
where they can be used as an effective treatment. Fur-
thermore, VRK1 has a dual role in DDR, since it also
participates in the early chromatin relaxation as a conse-
quence of DNA breaks and in individual steps of specific
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pathways, such as the phosphorylation of 53BP1 re-
quired for the assembly of 53BP1 foci [20]. In conse-
quence, VRK1 knockdown clearly alters the DNA-repair
process at different stages, from the early local chroma-
tin relaxation associated with H4K16 acetylation to
subsequent steps of DDR, such as H2AX, NBS1 and
53BP1 phosphorylation and accumulation, which are in-
dicators of overall damage.
VRK1 plays a crucial role in cell proliferation and
DNA repair processes, which, if inhibited, can lead to a
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reduction in tumor growth and an increase in its genetic
instability that can be manipulated for therapeutic pur-
poses, and perhaps also make the tumor more immuno-
genic. Furthermore, targeting VRK1 can also have
additional effects on tumor progression. High levels of
VRK1 has been associated as a bad prognostic indicator
to several tumors such as breast [27, 61, 62], gliomas
[28], colon [63], lung [47, 64], and hepatocarcinomas
[30] among others. Mechanistically, these high VRK1
levels facilitate tumor cell proliferation [22, 45, 65], me-
tastasis formation [66], and resistance to DNA damage
[20, 26] mediated by the activation of repair process in
chromatin [19] and by p53-mediated responses [52, 55,
56, 67, 68]. Therefore, the depletion of VRK1 will reduce
A
B
C
Fig. 6 Effect of the ATM inhibitor KU55933 on the formation of γH2AX (a) and 53BP1 (b) foci induced by olaparib in A549 cells. c. Detection of
VRK1 depletion in immunoblot. siC: siControl, siV: siVRK1–02. ns: not significant, ** p < 0.01, *** p < 0.001
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proliferative potential and impair the response to DNA
damage that will facilitate cell death. In a gene expres-
sion analysis of ninety-two human lung adenocarcin-
omas, which were compared to its matched controls,
high VRK1 expression levels were detected in mitotic
networks of lung adenocarcinomas, and its inhibition
cooperated with PARP inhibitors to reduce tumor
growth [47].
VRK1 plays a role in different steps of DDR [19] and
its impartment can sensitize cells to treatments based on
DNA damage by preventing the response. VRK1 knock-
down facilitates the synthetic lethality by combination of
A
B
Fig. 7 H4K16ac induced by olaparib is independent of ATM. a. Effect of VRK1 depletion on H4K16 acetylation induced by olaparib treatment in
HT144 (ATM−/−) cells. The field image used for quantification is shown in Additional file 10A: Figure S10A. b. Effect of VRK1 depletion on H4K16
acetylation induced by olaparib in A549 (ATM+/+) cells that were preincubated with the ATM inhibitor KU55933 for three hours before the
addition of olaparib. The field image used for quantification is shown in Additional file 10B: Figure S10B. siC: siControl, siV: siVRK1–02. ns: not
significant, *** p < 0.001
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olaparib and IR. The effect of VRK1 depletion on the cel-
lular response to olaparib, by itself or in combination with
IR, suggests that drugs targeting VRK1 might represent a
novel therapeutic tool when they are developed. There is
no inhibitor of VRK1, since its atypical catalytic site makes
it insensitive to kinase inhibitors as demonstrated by inter-
action assays [59, 60] and kinase assays [69], but its devel-
opment, considering its potential for a high specificity,
might be an important therapeutic advance for use in
combination therapies to minimize toxic drug doses, and
limit the potential for resistance. Furthermore, it is im-
portant to note that the effect of VRK1 is independent of
p53 or ATM and, thus, any potential new inhibitor target-
ing VRK1 could be used in cancers independently of their
mutational status. Eventually, this would also permit alter-
native drug combinations that will have to be determined,
and adjusted, for specific tumor types.
The dual effect of VRK1 depletion on reduction of cell
cycle progression and defective DDR implicates that the
absence of this kinase in arrested tumor stem cells can fa-
cilitate the accumulation of mutations. This effect could
lead to a loss of tumor cell viability, or, alternatively, to a
higher mutational load in tumor stem, or non-dividing,
cells that could potentially make them more amenable to
immunotherapy [70–73]. The combination of drugs tar-
geting different participants in DDR pathways is a suitable
form of cancer treatment that can result in reductions of
drug or radiation doses and their toxicity. Moreover, the
impairment of DDR by targeting new components of the
pathway will facilitate accumulation of genetic damage in
tumor cells, and make them more immunogenic and sus-
ceptible to new immunotherapeutic approaches.
Conclusion
VRK1 depletion impairs the DNA damage response in-
duced by olaparib, ionizing radiation and their combin-
ation, permitting a reduction in doses. Consequently,
development of VRK1 inhibitors can be useful to treat
tumor cells by impairing DNA repair processes, which
would contribute to improve the efficacy of current
treatments independently of the mutational status of
p53 and ATM, and by facilitating accumulation of DNA
damage that either lead to cell death, or make tumor
cells more immunogenic.
Additional files
Additional file 1: Figure S1. Effect of combinations of olaparib and
ionizing radiation on the formation of γH2AX and 53BP1 foci in response
to DNA damage in A549 cells. a. Effect of different doses of either
olaparib or ionizing radiation on the formation of γH2AX and 53BP1 foci
in response to DNA damage. b. Effect of combinations of olaparib and
ionizing radiation on the formation of γH2AX and 53BP1 foci. The images
(Fig. 1) show the detail of the subnuclear protein detected. The
quantifications were performed using fifty cells from different fields of
the experiments (usually between seven and ten were required). The
images selected for presentation in the main Fig. 1 are indicated by
boxes. (PDF 380 kb)
Additional file 2: Figure S2. Effect of combinations of olaparib and
ionizing radiation on the formation of γH2AX and 53BP1 foci in response
to DNA damage in H1299 (TP53−/−) cells. a. Effect of different doses of
either olaparib or ionizing radiation on the formation of γH2AX and
53BP1 foci in response to DNA damage. b. Effect of combinations of
olaparib and ionizing radiation on the formation of γH2AX and 53BP1
foci. c. Quantification of the effect of olaparib and IR by themselves or in
combination on the number of γH2AX foci. d. Quantification of the effect
of olaparib and IR, by themselves or in combination on the number of
53BP1 foci. ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001.
(PDF 350 kb)
Additional file 3: Figure S3. Effect of combinations of olaparib and
ionizing radiation on the formation of γH2AX and 53BP1 foci in response
to DNA damage in MDA-MB-231 breast cancer (triple negative) cells. a. Ef-
fect of different doses of either olaparib or ionizing radiation on the for-
mation of γH2AX and 53BP1 foci in response to DNA damage. b. Effect of
combinations of olaparib and ionizing radiation on the formation of
γH2AX and 53BP1 foci. c. Quantification of the effect of olaparib and IR
by themselves or in combination on the number of γH2AX foci. d.
Quantification of the effect of olaparib and IR, by themselves or in
combination on the number of 53BP1 foci. ns: not significant,
*** p < 0.001. (PDF 312 kb)
Additional file 4: Figure S4. Effect of VRK1 depletion on the nuclear
fluorescence associated to the acetylation of histone H4 in lysine 16
(H4K16ac ) induced by olaparib, IR or their combination in H1299 (TP53
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Fig. 8 Diagram illustrating different steps in the response to DNA
damage showing the cooperation of different treatments targeting
specific DDR proteins, which can functionally mimic their mutation.
The VRK1 inhibitor question mark means that they are not yet
available because they have not been designed
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−/−) cells deprived (0.5%) of serum. The images show the detail of the
subnuclear protein detected (Fig. 2). The quantifications were performed
using fifty cells from different fields of the experiments (usually between
seven and ten were required). The detail images selected for
presentation in Fig. 2 are indicated by boxes. (PDF 735 kb)
Additional file 5: Figure S5. Effect of VRK1 depletion on the nuclear
fluorescence associated to the acetylation of histone H4 in lysine 16
(H4K16 ac) induced by olaparib, IR or their combination in A549 (TP53
+/+) cells deprived (0.5%) of serum. a left. Effect of siControl (siC) on
A549 cells treated with different doses of olaparib, IR or their
combination on nuclear H4K16ac fluorescence. a right. Effect of siVRK1 on
A549 cells treated with different doses of olaparib, IR or their
combination on the acetylation of histone H4 in lysine 16. b.
Quantification of the effect of VRK1 depletion on the increase of nuclear
H4K16ac fluorescence induced by DNA damage. c. The immunoblot
shows the effect of VRK1 depletion on its protein level. ns: not significant.
*** p < 0.001. (PDF 950 kb)
Additional file 6: Figure S6. Effect of VRK1 depletion on the nuclear
NBS1 fluorescence induced by olaparib, IR or their combination in H1299
(TP53−/−) cells deprived (0.5%) of serum. The images show the detail of
the subnuclear protein detected (Fig. 3). The quantifications were
performed using fifty cells from different fields of the experiments
(usually between seven and ten were required). The detail images
selected for presentation in Fig. 3 are indicated by boxes. (PDF 596 kb)
Additional file 7: Figure S7. Effect of VRK1 depletion on nuclear NBS1
fluorescence induced by olaparib, IR or their combination in A549 (TP53+/+)
cells deprived of serum (0.5%). A Left. Effect of siControl on A549 cells
treated with different doses of olaparib, IR or their combination on the
NBS1 fluorescence. A Right. Effect of si-VRK1 on A549 cells treated with dif-
ferent doses of olaparib, IR or their combination on the accumulation of
NBS1 in nuclei. B. Quantification of the effect of VRK1 depletion on the in-
crease of nuclear NBS1 fluorescence by aggregation of this protein induced
by DNA damage. C. The immunoblot shows the effect of VRK1 depletion on
its protein level. ns: not significant, ** p < 0.01, *** p < 0.001. (PDF 901 kb)
Additional file 8: Figure S8. Effect of VRK1 depletion on nuclear NBS1
fluorescence induced by olaparib, IR or their combination in HT144 (ATM
−/−) cells deprived (0.5%) of serum. A left. Effect of siControl on HT144
cells treated with different doses of olaparib, IR or their combination on
the NBS1 fluorescence. A right. Effect of siVRK1 on HT144 cells treated
with different doses of olaparib, IR or their combination, on the
accumulation of NBS1 in nuclei. B. Quantification of the effect of VRK1
depletion on the increase of nuclear NBS1 fluorescence by aggregation
of this protein induced by DNA damage. c. The immunoblot shows the
effect of VRK1 depletion on its protein level. ns: not significant.
*** p < 0.001. (PDF 509 kb)
Additional file 9: Figure S9. Effect of VRK1 depletion on the formation
of γH2AX and 53BP1 foci induced by olaparib, IR or their combination in
H1299 (TP53−/−) cells. a. Effect of siControl on H1299 (TP53−/−) cells
treated with different doses of olaparib, IR or their combination on the
formation of γH2AX foci. b. Effect of siVRK1 on H1299 cells treated with
different doses of olaparib, IR or their combination on the formation of
53BP1 foci in H1299 (TP53−/−) cells. c. Detection of VRK1 depletion in
immunoblot. ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001.
(PDF 1248 kb)
Additional file 10: Figure S10. H4K16ac induced by olaparib is
independent of ATM. A. Effect of VRK1 depletion on H4K16 acetylation
induced by olaparib in HT144 (ATM−/−) cells. Field image used for
quantification of H4K16ac . The number of cells counted is indicated in
Fig. 7a. B. Effect of VRK1 depletion on H4K16 acetylation induced by
olaparib in A549 (ATM+/+) cells that were preincubated with the ATM
inhibitor KU55933 for three hours before the addition of olaparib. Field
image used for quantification of H4K16ac . The number of cells counted
is indicated in Fig. 7b. (PDF 414 kb)
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